Sironax is a privately held clinical-stage biotech developing experimental medicines and a brain-delivery platform intended to help drug developers move large biologic therapies across the blood-brain barrier. Novartis has exercised an option to acquire full global rights to the platform. Sironax is due to receive $125 million after the transaction closes and will keep rights to develop, manufacture and commercialize selected assets that use the technology.
The blood-brain barrier protects the brain but also complicates efforts to deliver potential medicines. Sironax says its proprietary modules are engineered to potentially enable the in vivo transport of monoclonal antibodies, peptides, proteins, gene therapies and other large biologics. The intended workflow is part of drug development: use a brain-delivery module with a therapeutic payload, then evaluate whether the approach can reach the brain and support a treatment program.
Sironax’s own drug pipeline sits alongside the delivery platform. It has three programs in Phase 1b/2 studies. SIR2501 is an allosteric SARM1 inhibitor being developed to prevent neuroaxonal damage in conditions including amyotrophic lateral sclerosis and chemotherapy-induced peripheral neuropathy; SIR4156 activates NAMPT and targets metabolic dysfunction; and SIR9900 inhibits RIPK1 as a potential treatment for inflammatory and immunological diseases.
At closing, Novartis would acquire the broader global platform rights, while Sironax would retain specified rights to selected assets. That structure gives Sironax two routes for its research: monetize platform intellectual property through an asset purchase and continue developing selected experimental medicines itself. The transaction transfers technology rights rather than ownership of Sironax.
The option exercise follows the agreement announced in July 2025, which gave Novartis an evaluation period before it could acquire the platform. Novartis has now made that election, but the latest announcement places the $125 million payment after closing. The consideration is for the technology asset, not an equity financing.
Sironax says it plans to direct the purchase proceeds toward its three clinical-stage programs and multiple earlier candidates. The next business test is whether that retained pipeline can generate clinical evidence even as control of the broader platform is set to pass to Novartis after closing.